The potential role of mTOR inhibitors in the treatment of endocrine tumors

Journal of Endocrinological Investigation

Volumn 33, Issue 4, 2010, Pages 276-281

  Grozinsky Glasberg, S ^a,b   Shimon, I ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

mTOR; Neuroendocrine; Pituitary; RAD001 (everolimus); Rapamycin; Thyroid

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

ADRENAL TUMOR; ANGIOGENESIS; APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CHROMAFFIN CELL; DRUG MECHANISM; ENDOCRINE TUMOR; HUMAN; LONGEVITY; NEUROENDOCRINE TUMOR; NONHUMAN; REVIEW; THYROID CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; ENDOCRINE GLAND NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ENDOCRINE GLAND NEOPLASMS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 77953606637     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03345792     Document Type: Review

References (42)

1. Kapahi P, Vijg J. Aging-lost in translation? N Engl J Med 2009, 361: 2669-70.
2. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006, 124: 471-84.
3. Luo J, Manning BD, Cantiey LC. Targeting the PI3K-Akt pathway in human cancer rationale and promise. Cancer Cell 2003, 4: 257-62. (Pubitemid 37329790)
4. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005, 17: 150-7.
5. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007, 12: 9-22.
6. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003, 3: 0371-7.
7. Bjomsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4: 335-48.
8. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5: 671-88. (Pubitemid 44151605)
9. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008, 50: 799-805. (Pubitemid 351354788)
10. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372: 449-56.
11. Okamoto I, Doi T, Ohtsu A et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010, 40: 17-23.
12. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26: 4311-8.
13. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007, 85: 54-60. (Pubitemid 46550026)
14. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007, 13: 3109-14.
15. Musat M, Korbonits M, Kola B et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005, 12: 423-33.
16. Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 2009, 16: 1329-38.
17. Gorshtein A, Rubinfeld H, Kendler E, et al. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 2009, 16: 1017-27.
18. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y et al. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol 2010, 315: 87-94.
19. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005, 24: 7455-64.
20. Zatelli MC, Minoia M, Filiert C, et al. Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2010, 95: 968-76.
21. Cerovac V, Monteserin-Garcia J, Rubinfeld H, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010, 70: 666-74.
22. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA Khan A The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 2000, 13: 882-7. (Pubitemid 30643836)
23. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998, 11: 169-74. (Pubitemid 28144152)
24. Romano MI, Grattone M, Kamer MP, et al. Relationship between the level of c-myc mRNA and histologic aggressiveness in thyroid tumors. Horm Res 1993, 39: 161-5. (Pubitemid 23322363)
25. Suh JM, Song JH, Kim DW et al. Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland. J Biol Chem 2003, 278: 21960-71.
26. Behlendorf T, Voigt W, Mueller T, Jordan K, Arnold D, Schmoll H. Activity of mTOR-lnhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines. J Clin Oncol 2009, 27 (Suppl): e14608 (abstract).
27. Papewalis C, Wuttke M, Schinner S, et al. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res 2009, 41: 752-6.
28. Furuya F, Lu C, Willingham MC, Cheng SY. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007, 28: 2451-8.
29. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009, 94: 4107-12.
30. Powers JF, Tischler AS, Cherington V. Discordant effects of rapamycin on proliferation and p70S6 kinase phosphorylation in normal and neoplastic rat chromaffin cells. Neurosci Lett 1999, 259: 137-40.
31. Podsypanina K, Lee RT, Politis C et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001, 98: 10320-5.
32. Wang L, Ignat A, Axiotis CA Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms. Appl Immunohistochem Mol Morphol 2002, 10: 139-46. (Pubitemid 34553170)
33. Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008, 87: 168-81. (Pubitemid 351563811)
34. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 2008, 15: 257-66. (Pubitemid 351449744)
35. De Martino MC, van Koetsveld P, Sprij-Mooij D, et al. Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines. Endocr Abstr 2009, 20: P52 (abstract).
36. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004, 22: 909-18.
37. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009, 2: 45.
38. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006, 95: 1148-54.
39. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010, 28: 69-76.
40. Duran I, Salazar R, Casanovas O, et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 2007, 18: 1307-13.
41. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 2009, 41: 697-702.
42. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003, 4: 343-8.